Does the media refer more to ABCL or IMTX?

In the previous week, AbCellera Biologics had 1 more articles in the media than Immatics. MarketBeat recorded 4 mentions for AbCellera Biologics and 3 mentions for Immatics. AbCellera Biologics' average media sentiment score of 0.17 beat Immatics' score of 0.02 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor EWTX or IMTX?

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Immatics. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 3 mentions for Immatics. Edgewise Therapeutics' average media sentiment score of 0.51 beat Immatics' score of 0.02 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings and valuation, TNGX or IMTX?

Tango Therapeutics has higher revenue and earnings than Immatics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tango Therapeutics $62.38M 59.01 -$101.59M -$0.85 N/A Immatics $54.60M 18.65 -$222.26M -$1.86 N/A

Does the media refer more to TNGX or IMTX?

In the previous week, Tango Therapeutics had 3 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Tango Therapeutics and 3 mentions for Immatics. Tango Therapeutics' average media sentiment score of 0.79 beat Immatics' score of 0.02 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, IMTX or RLAY?

Immatics has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immatics $54.60M 18.65 -$222.26M -$1.86 N/A Relay Therapeutics $15.35M 256.26 -$276.48M -$1.57 N/A

Does the media prefer IMTX or RLAY?

In the previous week, Immatics had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 3 mentions for Immatics and 1 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.87 beat Immatics' score of 0.02 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Relay Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor IMTX or PBLS?

In the previous week, Immatics had 1 more articles in the media than Parabilis Medicines. MarketBeat recorded 3 mentions for Immatics and 2 mentions for Parabilis Medicines. Immatics' average media sentiment score of 0.02 beat Parabilis Medicines' score of -0.13 indicating that Immatics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Parabilis Medicines 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Immatics (IMTX) Competitors

$7.37 -0.08 (-1.07%)

Closing price 04:00 PM Eastern

Extended Trading

$7.38 +0.00 (+0.07%)

As of 04:42 PM Eastern

Compare

IMTX vs. ABCL, EWTX, TNGX, RLAY, and PBLS

Should you buy Immatics stock or one of its competitors? Immatics's main competitors and comparable companies include AbCellera Biologics (ABCL), Edgewise Therapeutics (EWTX), Tango Therapeutics (TNGX), Relay Therapeutics (RLAY), and Parabilis Medicines (PBLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immatics compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Immatics (NASDAQ:IMTX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by insiders. Comparatively, 3.3% of Immatics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, AbCellera Biologics had 1 more articles in the media than Immatics. MarketBeat recorded 4 mentions for AbCellera Biologics and 3 mentions for Immatics. AbCellera Biologics' average media sentiment score of 0.17 beat Immatics' score of 0.02 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

AbCellera Biologics has a net margin of -248.83% compared to Immatics' net margin of -495.71%. AbCellera Biologics' return on equity of -17.49% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Immatics	-495.71%	-47.41%	-39.45%

AbCellera Biologics has higher revenue and earnings than Immatics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	52.36	-$146.41M	-$0.54	N/A
Immatics	$54.60M	18.65	-$222.26M	-$1.86	N/A

AbCellera Biologics has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Immatics has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

AbCellera Biologics presently has a consensus price target of $13.38, indicating a potential upside of 4.25%. Immatics has a consensus price target of $20.60, indicating a potential upside of 176.51%. Given Immatics' higher probable upside, analysts clearly believe Immatics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

AbCellera Biologics beats Immatics on 13 of the 17 factors compared between the two stocks.

How does Immatics compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Immatics (NASDAQ:IMTX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Edgewise Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Immatics has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Immatics. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 3 mentions for Immatics. Edgewise Therapeutics' average media sentiment score of 0.51 beat Immatics' score of 0.02 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Edgewise Therapeutics has higher earnings, but lower revenue than Immatics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Immatics	$54.60M	18.65	-$222.26M	-$1.86	N/A

Edgewise Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Edgewise Therapeutics' return on equity of -39.01% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Immatics	-495.71%	-47.41%	-39.45%

Edgewise Therapeutics presently has a consensus price target of $51.33, indicating a potential upside of 29.73%. Immatics has a consensus price target of $20.60, indicating a potential upside of 176.51%. Given Immatics' higher probable upside, analysts plainly believe Immatics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

64.4% of Immatics shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by insiders. Comparatively, 3.3% of Immatics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Edgewise Therapeutics beats Immatics on 11 of the 16 factors compared between the two stocks.

How does Immatics compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Immatics (NASDAQ:IMTX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Tango Therapeutics has higher revenue and earnings than Immatics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	59.01	-$101.59M	-$0.85	N/A
Immatics	$54.60M	18.65	-$222.26M	-$1.86	N/A

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tango Therapeutics currently has a consensus price target of $43.46, suggesting a potential upside of 99.09%. Immatics has a consensus price target of $20.60, suggesting a potential upside of 176.51%. Given Immatics' higher possible upside, analysts clearly believe Immatics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Tango Therapeutics had 3 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Tango Therapeutics and 3 mentions for Immatics. Tango Therapeutics' average media sentiment score of 0.79 beat Immatics' score of 0.02 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Tango Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, Immatics has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

Tango Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Tango Therapeutics' return on equity of -25.75% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
Immatics	-495.71%	-47.41%	-39.45%

Summary

Tango Therapeutics beats Immatics on 13 of the 16 factors compared between the two stocks.

How does Immatics compare to Relay Therapeutics?

Immatics (NASDAQ:IMTX) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

In the previous week, Immatics had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 3 mentions for Immatics and 1 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.87 beat Immatics' score of 0.02 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Relay Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

64.4% of Immatics shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Relay Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Relay Therapeutics' return on equity of -42.27% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-495.71%	-47.41%	-39.45%
Relay Therapeutics	N/A	-42.27%	-38.67%

Immatics currently has a consensus target price of $20.60, suggesting a potential upside of 176.51%. Relay Therapeutics has a consensus target price of $25.92, suggesting a potential upside of 44.38%. Given Immatics' higher probable upside, analysts clearly believe Immatics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Immatics has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.72, meaning that its share price is 72% more volatile than the broader market.

Immatics has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	18.65	-$222.26M	-$1.86	N/A
Relay Therapeutics	$15.35M	256.26	-$276.48M	-$1.57	N/A

Summary

Relay Therapeutics beats Immatics on 12 of the 17 factors compared between the two stocks.

How does Immatics compare to Parabilis Medicines?

Immatics (NASDAQ:IMTX) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

In the previous week, Immatics had 1 more articles in the media than Parabilis Medicines. MarketBeat recorded 3 mentions for Immatics and 2 mentions for Parabilis Medicines. Immatics' average media sentiment score of 0.02 beat Parabilis Medicines' score of -0.13 indicating that Immatics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Parabilis Medicines	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immatics presently has a consensus price target of $20.60, suggesting a potential upside of 176.51%. Parabilis Medicines has a consensus price target of $41.67, suggesting a potential upside of 44.58%. Given Immatics' higher probable upside, analysts plainly believe Immatics is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Parabilis Medicines has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Parabilis Medicines' return on equity of 0.00% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-495.71%	-47.41%	-39.45%
Parabilis Medicines	N/A	N/A	N/A

Parabilis Medicines has lower revenue, but higher earnings than Immatics. Parabilis Medicines is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	18.65	-$222.26M	-$1.86	N/A
Parabilis Medicines	N/A	N/A	-$145.89M	-$2.13	N/A

64.4% of Immatics shares are held by institutional investors. 3.3% of Immatics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Immatics beats Parabilis Medicines on 9 of the 15 factors compared between the two stocks.

Get Immatics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMTX vs. The Competition

Export

Metric	Immatics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.01B	$3.83B	$7.14B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	-3.96	13.96	275.15	25.94
Price / Sales	18.45	1,177.93	566.78	83.59
Price / Cash	N/A	118.37	77.41	52.81
Price / Book	1.80	16.11	10.80	6.27
Net Income	-$222.26M	-$22.69M	$3.50B	$382.13M
7 Day Performance	-12.68%	-3.47%	-2.02%	-1.39%
1 Month Performance	-21.93%	-12.68%	-7.54%	-5.62%
1 Year Performance	-28.93%	9.60%	3.31%	-1.54%

Immatics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMTX Immatics	3.5616 of 5 stars	$7.37 -1.1%	$20.60 +179.5%	-20.8%	$1.01B	$54.60M	N/A	704
ABCL AbCellera Biologics	1.6187 of 5 stars	$14.82 +6.5%	$13.38 -9.8%	+122.4%	$4.54B	$75.13M	N/A	562	Gap Down
EWTX Edgewise Therapeutics	2.8582 of 5 stars	$39.19 -1.5%	$51.33 +31.0%	+161.4%	$4.26B	N/A	N/A	127
TNGX Tango Therapeutics	3.0028 of 5 stars	$24.42 +0.5%	$43.46 +78.0%	+199.5%	$4.12B	$62.38M	N/A	137	Insider Trade
RLAY Relay Therapeutics	2.5764 of 5 stars	$18.36 +3.8%	$25.92 +41.2%	+207.9%	$4.02B	$15.35M	N/A	192

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMTX) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immatics (IMTX) Competitors

IMTX vs. ABCL, EWTX, TNGX, RLAY, and PBLS

How does Immatics compare to AbCellera Biologics?

Summary

How does Immatics compare to Edgewise Therapeutics?

Summary

How does Immatics compare to Tango Therapeutics?

Summary

How does Immatics compare to Relay Therapeutics?

Summary

How does Immatics compare to Parabilis Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX vs. The Competition

Immatics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immatics (IMTX) Competitors

IMTX vs. ABCL, EWTX, TNGX, RLAY, and PBLS

How does Immatics compare to AbCellera Biologics?

Do insiders & institutionals have more ownership in ABCL or IMTX?

Does the media refer more to ABCL or IMTX?

Is ABCL or IMTX more profitable?

Which has preferable valuation & earnings, ABCL or IMTX?

Which has more volatility & risk, ABCL or IMTX?

Do analysts rate ABCL or IMTX?

Summary

How does Immatics compare to Edgewise Therapeutics?

Which has more risk and volatility, EWTX or IMTX?

Does the media favor EWTX or IMTX?

Which has preferable valuation & earnings, EWTX or IMTX?

Is EWTX or IMTX more profitable?

Do analysts rate EWTX or IMTX?

Do insiders and institutionals believe in EWTX or IMTX?

Summary

How does Immatics compare to Tango Therapeutics?

Which has higher earnings and valuation, TNGX or IMTX?

Do insiders and institutionals hold more shares of TNGX or IMTX?

Do analysts recommend TNGX or IMTX?

Does the media refer more to TNGX or IMTX?

Which has more risk and volatility, TNGX or IMTX?

Is TNGX or IMTX more profitable?

Summary

How does Immatics compare to Relay Therapeutics?

Does the media prefer IMTX or RLAY?

Do insiders & institutionals hold more shares of IMTX or RLAY?

Is IMTX or RLAY more profitable?

Do analysts prefer IMTX or RLAY?

Which has more volatility & risk, IMTX or RLAY?

Which has stronger earnings and valuation, IMTX or RLAY?

Summary

How does Immatics compare to Parabilis Medicines?

Does the media favor IMTX or PBLS?

Do analysts prefer IMTX or PBLS?

Is IMTX or PBLS more profitable?

Which has better valuation and earnings, IMTX or PBLS?

Do institutionals and insiders hold more shares of IMTX or PBLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX vs. The Competition

Immatics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools